Migraine treatment throughout the lifecycle

References

• Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41, 646–657 (2001).
   PubMed Web of Science ®Google Scholar
• MenkenM, Munsat TL, Toole JF. The Global Burden of Disease Study: implications for neurology. Arch. Neurol. 57, 418–420 (2000).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 58, 885–894 (2002).
   PubMed Web of Science ®Google Scholar
• Gordon KE, Dooley JM, Wood EP. Prevalence of reported migraine headaches in Canadian adolescents. Can. J. Neurol. Sci. 31(3), 324–327 (2004).
   PubMed Web of Science ®Google Scholar
• MacGregorEA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation (MAZE) survey. Headache 43, 19–26 (2003).
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(Suppl. 7), 1–96 (1988).
   Web of Science ®Google Scholar
• OlesenJ. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia 24(Suppl. 1), 1–160 (2004).
   Web of Science ®Google Scholar
• Schreiber CP, Hutchinson S, Webster CJ, Ames M, Richardson MS, Powers C. Prevalence of migraine in patients with a history of self-reported or physician-diagnosed “sinus” headache. Arch. Intern. Med. 164, 1769–1772 (2004).
   PubMed Web of Science ®Google Scholar
• KanieckiRG. Migraine and tension-type headache. An assessment of challenges in diagnosis. Neurology 58(Suppl. 6), 15–20 (2002).
   PubMed Web of Science ®Google Scholar
• Patel NV, Bigal ME, Kolodner KB, Leotta C, Lafata JE, Lipton RB. Prevalence and impact of migraine and probable migraine in a health plan. Neurology 63, 1432–1438 (2004).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Steiner TJ, Silberstein SD, Olesen J. Classification of primary headaches. Neurology 63, 427–435 (2004).
   PubMed Web of Science ®Google Scholar
• Welch KMA. Contemporary concepts of migraine pathogenesis. Neurology 61(Suppl. 4), 2–8 (2003).
   PubMed Web of Science ®Google Scholar
• PappagaloM, Szabo Z, Esposito G, Lokesh A, Velez L. Imaging neurogenic inflammation in patients with migraine headaches. Neurology 52, 274–275 (2002).
   Web of Science ®Google Scholar
• GoadsbyPJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N. Engl. J. Med. 346(4), 257–270 (2002).
   PubMed Web of Science ®Google Scholar
• LandyS, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine: implications for treatment. CNS Drugs 18(6), 337–342 (2004).
   PubMed Web of Science ®Google Scholar
• Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5-HT1B/1D receptor agonists. Proc. Natl Acad. Sci. USA 101, 4274–4279 (2004).
   PubMed Web of Science ®Google Scholar
• Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann. Neurol. 55, 19–26 (2004).
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Sholtzow M, Young WB. Prevalence of mechanical (brush) allodynia in migraine. Presented at the 56th Annual Meeting, San Francisco, CA, USA, P01.157 (2004).
   Google Scholar
• Burstein R, Yarnitsky D, Goor-Aryeh I et al. An association between migraine and cutaneous allodynia. Ann. Neurol. 47, 614–624 (2000).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology 63, 848–852 (2004).
   PubMed Web of Science ®Google Scholar
• Cady RK, Sheftell F, Lipton RB et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther. 9, 1035–1048 (2000).
   Google Scholar
• HuXH, Raskin NH, Cowan R et al. Treatment of migraine with rizatriptan: when to take the medication. Headache 42, 16–20 (2002).
   PubMed Web of Science ®Google Scholar
• ScholppJ, Schellenberg R, Moeckesch B, Banik N. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia 24, 925–933 (2004).
   PubMed Web of Science ®Google Scholar
• KlapperJ, Lucas C, Rosjo O, Charlesworth B. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 24(11), 918–924 (2004).
   PubMed Web of Science ®Google Scholar
• PascualJ, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 42, 28–31 (2002).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kailasam J, Seifert T. Early treatment of migraine with rizatriptan: a placebo-controlled study. Presented at the 56th Annual Meeting, San Francisco, CA, USA, S21.005 (2004).
   Google Scholar
• Winner P, Mannix LK, Putnam DG et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin. Proc. 78, 1214–1222 (2003).
   PubMed Web of Science ®Google Scholar
• LandyS, Savani N, Shackelford S, Loftus J, Jones M. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int. J. Clin. Pract. 58, 913–919 (2004).
   PubMed Web of Science ®Google Scholar
• CarpayJ, Schoenen J, Ahmad F, Kinrade F, Boswell D. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin. Ther. 2, 214–223 (2004).
   Google Scholar
• BrandesJL, Roberson S, Hilliard B, Sikes C, Tiseo P. Early treatment of migraine: a prospective, double-blind, placebo-controlled trial of eletriptan in the early stages of attack. Presented at the 46th Annual Scientific Meeting of the American Headache Society, Vancouver, British Columbia, Canada, F41 (2004).
   Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358, 1668–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Migraine. Lancet 363, 381–391 (2004).
   PubMed Web of Science ®Google Scholar
• Imitrex Injection. In: Physicians’ Desk Reference. Thomson Healthcare 58th Edition. NJ, USA, 1519–1523 (2004).
   Google Scholar
• Winner P, Adelman J, Aurora S, Ames M, Lener M. Pain-free results of sumatriptan 6 mg SC in the treatment of morning migraine: results from two prospective, randomized, double-blind, placebo-controlled studies. Presented at the 45th Annual Scientific Meeting of the American Headache Society, Chicago, IL, USA, F41 (2003).
   Google Scholar
• KanieckiRG. Mixing sumatriptan: a prospective study of stratified care using multiple formulations. Headache 41, 862–866 (2001).
   PubMed Web of Science ®Google Scholar
• DahlofC. Clinical applications of new therapeutic deliveries in migraine. Neurology 61(Suppl. 4), 31–34 (2003).
   PubMedGoogle Scholar
• NappiG, Sandrini G, Sances G. Tolerability of the triptans: clinical implications. Drug Safety 26(2), 93–107 (2003).
   PubMed Web of Science ®Google Scholar
• DodickD, Lipton RB, Martin V et al. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D) agonists in the acute treatment of migraine. Headache 44, 414–425 (2004).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 43, 144–166 (2003).
   PubMed Web of Science ®Google Scholar
• Snow V, Weiss K, Wall EM, Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann. Intern. Med. 137(10), 840–847 (2002).
   PubMed Web of Science ®Google Scholar
• Evans RW, Atriham AR. QT prolongation with migraine medications. Headache 43, 809–810 (2003).
   PubMed Web of Science ®Google Scholar
• Romero CE, Baron JD, Knox AP, Hinchey JA, Ropper AH. Barbiturate withdrawal following internet purchase of fioricet. Arch. Neurol. 61(7), 1111–1112 (2004).
   PubMed Web of Science ®Google Scholar
• FreitagFG, Cady R, DiSerio F et al. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Headache 41(4), 391–398 (2001).
   PubMed Web of Science ®Google Scholar
• LandyS, Richardson M, O’Quinn S. Migraine, midrin, and imitrex. Headache 42, 322–323 (2002).
   PubMed Web of Science ®Google Scholar
• Evans RW, Loder E, Biondi DM. When can successful migraine prophylaxis be discontinued? Headache 44, 1040–1042 (2004).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 22, 491–512 (2002).
   PubMed Web of Science ®Google Scholar
• BulutS, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin. Neurol. Neurosurgery 107, 44–48 (2004).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. 61, 490–495 (2004).
   PubMed Web of Science ®Google Scholar
• BrandesJL, Saper JR, Diamond M et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 25 (291), 965–973 (2004).
   Google Scholar
• Mathew NT, Rapoport A, Saper J et al. Efficacy of gabapentin in migraine prophylaxis. Headache 41, 119–128 (2001).
   PubMed Web of Science ®Google Scholar
• TronvikE, Stovner LJ, Helde G et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 289, 65–69 (2003).
   PubMed Web of Science ®Google Scholar
• RuoffGE. Migraine: effective pharmacologic strategies for prevention and treatment. Headache Pain 14(2), 75–82 (2004).
   Google Scholar
• MukherjeeDM, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286, 954–959 (2001).
   PubMed Web of Science ®Google Scholar
• BlumenfeldA. Botulinum toxin type A for the treatment of headache: pro. Headache 44, 825–830 (2004).
   PubMed Web of Science ®Google Scholar
• WelchKMA. Botulinum toxin type A for the treatment of headache: con. Headache 44, 831–833 (2004).
   PubMed Web of Science ®Google Scholar
• Evers S, Vollmer-Haase J, Schwang S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine-a randomized, double-blind, placebo-controlled study. Cephalalgia 24(10), 838–843 (2004).
   PubMed Web of Science ®Google Scholar
• TroostBT. Botulinum toxin type A (Botox) in the treatment of migraine and other headaches. Expert Rev. Neurotherapeutics 4(1), 27–31 (2004).
   PubMedGoogle Scholar
• Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S. Practice parameter: pharmacological treatment of migraine headache in children and adolescents. Neurology 63, 2215–2224 (2004).
   PubMed Web of Science ®Google Scholar
• BrousseauDC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann. Emerg. Med. 43, 256–262 (2004).
   PubMed Web of Science ®Google Scholar
• ChutkaDS, Takahashi PY, Hoel RW. Inappropriate medications for elderly patients. Mayo Clin. Proc. 79, 122–139 (2004).
   PubMed Web of Science ®Google Scholar
• MannixLK. Management of menstrual migraine. Neurologist 9, 207–213 (2003).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 63(2), 261–269 (2004).
   PubMed Web of Science ®Google Scholar
• Newman L, Mannix LK, Landy S et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 41, 248–256 (2001).
   PubMed Web of Science ®Google Scholar
• LoderE. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs 17(1), 1–7 (2003).
   PubMed Web of Science ®Google Scholar
• Durham PL. CGRP-receptor antagonists – a fresh approach to migraine therapy? N. Engl. J. Med. 350(11), 1073–1075 (2004).
   PubMed Web of Science ®Google Scholar
• OlesenJ, Diener H-C, Husstedt IW et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350(11), 1104–1110 (2004).
   PubMed Web of Science ®Google Scholar